Chemistry:Delgocitinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Corectim |
| Other names | JTE-052; JTE-052A |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C16H18N6O |
| Molar mass | 310.361 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.[2]
Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[3]
References
- ↑ 1.0 1.1 "Delgocitinib: First Approval". Drugs 80 (6): 609–615. April 2020. doi:10.1007/s40265-020-01291-2. PMID 32166597.
- ↑ "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". August 5, 2020. https://www.empr.com/home/news/delgocitinib-cream-leo-pharma-chronic-hand-eczema.
- ↑ "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms 8 (11): 1743. November 2020. doi:10.3390/microorganisms8111743. PMID 33172122.
 |  |
